LL-37 peptide claims on TikTok: what the science actually says

What's this video probably claiming?

Based on the hashtags #skye, #LL37, and #peptide, this creator is almost certainly discussing LL-37, a human cathelicidin antimicrobial peptide that has picked up serious traction in peptide-curious corners of TikTok. The hashtag #skye likely refers to a compounded or branded formulation name, which is a common way telehealth-adjacent creators signal a product without technically advertising it. Expect the video to frame LL-37 as an immune-modulating, antimicrobial, or even anti-inflammatory compound worth adding to a peptide stack. Some creators in this space go further, suggesting LL-37 can address chronic infections, gut dysbiosis, or respiratory conditions. The tone is typically personal testimonial dressed up with enough scientific terminology to sound credible. That framing is exactly what makes it worth scrutinizing.

What does the science actually show?

LL-37 is a real peptide. It is the only known human cathelicidin and it does have documented antimicrobial and immunomodulatory properties in laboratory settings. A 2010 study by Vandamme et al. in Cellular and Molecular Life Sciences characterized its broad-spectrum activity against bacteria, fungi, and some viruses. More recent work, including Mookherjee et al. (2020) in Nature Reviews Drug Discovery, confirmed LL-37 modulates innate immune signaling and can dampen or amplify inflammation depending on context. Here is the problem: nearly all of this data comes from in vitro cell studies or animal models. Human pharmacokinetic data for exogenously administered LL-37 is thin. A 2012 phase I trial by Nijnik et al. showed dose-dependent toxicity concerns at higher concentrations. The peptide is also rapidly degraded by proteases, meaning oral bioavailability is essentially zero and injection pharmacokinetics remain poorly characterized in humans.

Where does the social media noise diverge from clinical reality?

The gap between bench research and TikTok claims is substantial. Creators in the LL-37 space routinely imply it can fight chronic Lyme disease, resolve gut permeability issues, or serve as a broad immune booster. None of those applications have controlled human trial support. The Mookherjee 2020 review specifically notes that LL-37's context-dependent immunomodulation is a double-edged property: the same mechanism that could suppress harmful inflammation has also been associated with promoting certain cancer cell proliferation in vitro, as documented by Coffelt et al. (2009) in Clinical Cancer Research. That finding almost never appears in social media coverage. Additionally, most compounded LL-37 products circulating in the wellness space have no published stability, sterility, or dose-linearity data. Calling it a peptide therapy the way you would BPC-157 or GHK-Cu overstates what the human evidence currently supports.

What should you actually know?

LL-37 is a genuinely interesting area of immunology research. That is not the same thing as a validated therapy ready for self-administration. If you are considering it through a telehealth or compounding channel, the questions worth asking are: What route of administration are they proposing, and what pharmacokinetic data supports that route in humans? Has the compounding pharmacy undergone USP 797 sterility testing for this specific formulation? Is there a documented clinical rationale for your specific condition, or is this speculative optimization? The honest answer right now is that human evidence is sparse, safety data at therapeutic doses is incomplete, and regulatory status in the U.S. places LL-37 in a gray zone for compounding. Enthusiasm from a 18,000-view TikTok is not a substitute for that missing data.